Immucell (ICCC) Operating Leases (2020 - 2025)
Historic Operating Leases for Immucell (ICCC) over the last 6 years, with Q3 2025 value amounting to $4.1 million.
- Immucell's Operating Leases fell 80.23% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 80.23%. This contributed to the annual value of $4.6 million for FY2024, which is 1187.28% up from last year.
- According to the latest figures from Q3 2025, Immucell's Operating Leases is $4.1 million, which was down 80.23% from $4.1 million recorded in Q2 2025.
- Immucell's 5-year Operating Leases high stood at $4.7 million for Q1 2024, and its period low was $1.0 million during Q4 2021.
- Over the past 5 years, Immucell's median Operating Leases value was $4.0 million (recorded in 2024), while the average stood at $2.9 million.
- Per our database at Business Quant, Immucell's Operating Leases skyrocketed by 29921.27% in 2023 and then plummeted by 1180.43% in 2025.
- Quarter analysis of 5 years shows Immucell's Operating Leases stood at $1.0 million in 2021, then skyrocketed by 118.97% to $2.2 million in 2022, then skyrocketed by 81.27% to $4.1 million in 2023, then grew by 11.87% to $4.6 million in 2024, then dropped by 9.78% to $4.1 million in 2025.
- Its Operating Leases stands at $4.1 million for Q3 2025, versus $4.1 million for Q2 2025 and $4.1 million for Q1 2025.